|
시장보고서
상품코드
1338916
알포트증후군 치료 시장 점유율, 규모, 동향, 산업 분석 보고서 : 제품 유형별, 질병 유형별, 투여 경로별, 유통 채널별, 최종사용자별, 지역별, 부문별 예측(2023-2032년)Alport Syndrome Treatment Market Share, Size, Trends, Industry Analysis Report, By Product Type; By Disease Type; By Route Of Administration; By Distribution Channel (Online and Offline); By End User; By Region; Segment Forecast, 2023 - 2032 |
||||||
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
Polaris Market Research의 최신 조사에 따르면, 세계 알포트증후군 치료 시장 규모는 2032년까지 1,900만 달러에 달할 것으로 예상됩니다. 이 조사 보고서는 현재 시장 역학에 대한 자세한 인사이트와 향후 시장 성장에 대한 분석을 제공합니다.
시장 성장의 주요 요인은 알포트증후군을 치료하기 위한 임상 연구의 증가에 있습니다. 예를 들어, 엘록스 파마슈티컬스(Eloxx Pharmaceuticals)의 발표에 따르면, 2023년 2월 비센스 돌연변이 환자의 알포트증후군을 치료하기 위한 ELX-02의 임상 2상 연구의 첫 번째 참가자가 등록됐습니다. 이번 2상 임상시험에서는 COL4 유전자에 비센스 돌연변이가 있는 약 8명의 알포트증후군 환자가 치료를 받게 됩니다. 환자들은 2개월의 투약과 3개월의 검진을 받게 됩니다.
또한, 알포트증후군 치료의 기술 개발이 증가함에 따라 시장이 확대되고 있습니다. 예를 들어, 2021년 7월, 쿄와킬린(Kyowa Kirin)은 알포트증후군 치료제로 바르덱솔론메틸(RTA 402)을 신약으로 승인 신청했습니다. 리타가 알포트증후군 환자를 대상으로 실시한 CARDINAL 3상 임상시험의 유효성 및 안전성 정보가 이 신청의 근거가 되었습니다. 쿄와기린 그룹 각사는 생명과학과 기술의 진보를 추구하고 새로운 가치를 창출함으로써 전 세계인의 건강과 삶의 질을 향상시키기 위해 노력하고 있습니다. 따라서 이 치료제에 대한 임상시험의 증가는 예측 기간 동안 시장 성장을 견인할 것입니다.
또한, 알포트증후군 및 관련 증상을 치료하기 위한 약물 연구 및 개발(R& D)에 대한 주요 기업 및 정부의 노력으로 많은 투자가 이루어지고 있어 시장은 크게 성장할 것으로 예상됩니다. 예를 들어, 2021년 8월 Travere Therapeutics는 스파르탄 경구 현탁액의 안전성, 유효성, 내약성 및 108주간의 치료 기간 동안 1일 1회 투여 후 단백뇨의 변화를 평가하기 위해 임상 2상 연구를 진행했습니다. 그 결과, 진단 검사가 채택되고 더 널리 사용됨에 따라 시장이 발전할 것으로 예상됩니다.
알포트증후군 치료 시장 보고서 - 하이라이트
병원 약국 분야는 예측 기간 동안 높은 CAGR로 성장할 것으로 예상됩니다. 병원은 헬스케어 비지니스의 중요한 구성요소입니다.
알포트증후군 치료 시장에서 정제는 편의성, 기술 발전, 비용 효율성으로 인해 큰 성장세를 보일 것으로 예상됩니다.
아시아태평양이 압도적인 시장 점유율을 차지하고 있습니다. 이는 제네릭 의약품 제조업체의 증가와 신부전 및 관련 질환의 빈번한 발생에 기인합니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 세계의 알포트증후군 치료 시장 인사이트
- 알포트증후군 치료 - 업계 현황
- 알포트증후군 치료 시장 역학
- 성장 촉진요인과 기회
- 알포트증후군 유병률 상승
- 연구개발 활동 증가
- 성장 억제요인과 과제
- 숙련된 전문가 부족
- 성장 촉진요인과 기회
- PESTLE 분석
- 알포트증후군 치료 업계 동향
- COVID-19 감염증의 영향 분석
제5장 세계의 알포트증후군 치료 시장, 제품 유형별
- 주요 조사 결과
- 서론
- 태블릿
- 캡슐
- 주사제
- 기타
제6장 세계의 알포트증후군 치료 시장, 질환 종류별
- 주요 조사 결과
- 서론
- X연관 알포트증후군
- 상염색체 열성 알포트증후군
- 상염색체 우성 알포트증후군
제7장 세계의 알포트증후군 치료 시장, 투여 경로별
- 주요 조사 결과
- 서론
- 어랄
- 비경구
- 기타
제8장 세계의 알포트증후군 치료 시장, 최종사용자별
- 주요 조사 결과
- 서론
- 병원 약국
- 소매 약국
- 전문 클리닉
제9장 세계의 알포트증후군 치료 시장, 유통 채널별
- 주요 조사 결과
- 서론
- 온라인
- 오프라인
제10장 세계의 알포트증후군 치료 시장, 지역별
- 주요 조사 결과
- 서론
- 알포트증후군 치료 시장 평가, 지역별, 2019-2032년
- 알포트증후군 치료 시장 - 북미
- 북미 : 알포트증후군 치료 시장, 제품 유형별, 2019-2032년
- 북미 : 알포트증후군 치료 시장, 최종사용자별, 2019-2032년
- 북미 : 알포트증후군 치료 시장, 질환 유형별, 2019-2032년
- 북미 : 알포트증후군 치료 시장, 투여 경로별, 2019-2032년
- 북미 : 알포트증후군 치료 시장, 유통 채널별, 2019-2032년
- 알포트증후군 치료 시장 - 미국
- 알포트증후군 치료 시장 - 캐나다
- 알포트증후군 치료 시장 - 유럽
- 유럽 : 알포트증후군 치료 시장, 제품 유형별, 2019-2032년
- 유럽 : 알포트증후군 치료 시장, 최종사용자별, 2019-2032년
- 유럽 : 알포트증후군 치료 시장, 질환 유형별, 2019-2032년
- 유럽 : 알포트증후군 치료 시장, 투여 경로별, 2019-2032년
- 유럽 : 알포트증후군 치료 시장, 유통 채널별, 2019-2032년
- 알포트증후군 치료 시장 - 영국
- 알포트증후군 치료 시장 - 프랑스
- 알포트증후군 치료 시장 - 독일
- 알포트증후군 치료 시장 - 이탈리아
- 알포트증후군 치료 시장 - 스페인
- 알포트증후군 치료 시장 - 네델란드
- 알포트증후군 치료 시장 - 러시아
- 알포트증후군 치료 시장 - 아시아태평양
- 아시아태평양 : 알포트증후군 치료 시장, 제품 유형별, 2019-2032년
- 아시아태평양 : 알포트증후군 치료 시장, 최종사용자별, 2019-2032년
- 아시아태평양 : 알포트증후군 치료 시장, 질환 유형별, 2019-2032년
- 아시아태평양 : 알포트증후군 치료 시장, 투여 경로별, 2019-2032년
- 아시아태평양 : 알포트증후군 치료 시장, 유통 채널별, 2019-2032년
- 알포트증후군 치료 시장 - 중국
- 알포트증후군 치료 시장 - 인도
- 알포트증후군 치료 시장 - 일본
- 알포트증후군 치료 시장 - 말레이시아
- 알포트증후군 치료 시장 - 인도네시아
- 알포트증후군 치료 시장 - 한국
- 알포트증후군 치료 시장 - 중동 및 아프리카
- 중동 및 아프리카 : 알포트증후군 치료 시장, 제품 유형별, 2019-2032년
- 중동 및 아프리카 : 알포트증후군 치료 시장, 최종사용자별, 2019-2032년
- 중동 및 아프리카 : 알포트증후군 치료 시장, 질환 유형별, 2019-2032년
- 중동 및 아프리카 : 알포트증후군 치료 시장, 투여 경로별, 2019-2032년
- 중동 및 아프리카 : 알포트증후군 치료 시장, 유통 채널별, 2019-2032년
- 알포트증후군 치료 시장 - 사우디아라비아
- 알포트증후군 치료 시장 - 아랍에미리트
- 알포트증후군 치료 시장 - 이스라엘
- 알포트증후군 치료 시장 - 남아프리카공화국
- 알포트증후군 치료 시장 - 라틴아메리카
- 라틴아메리카 : 알포트증후군 치료 시장, 제품 유형별, 2019-2032년
- 라틴아메리카 : 알포트증후군 치료 시장, 최종사용자별, 2019-2032년
- 라틴아메리카 : 알포트증후군 치료 시장, 질환 유형별, 2019-2032년
- 라틴아메리카 : 알포트증후군 치료 시장, 투여 경로별, 2019-2032년
- 라틴아메리카 : 알포트증후군 치료 시장, 유통 채널별, 2019-2032년
- 알포트증후군 치료 시장 - 멕시코
- 알포트증후군 치료 시장 - 브라질
- 알포트증후군 치료 시장 - 아르헨티나
제11장 경쟁 상황
- 확장과 인수 분석
- 확대
- 인수
- 제휴/협업/합의/공개
제12장 기업 개요
- AstraZeneca
- Centogene
- Eurofins Discovery
- Eurofins LifeCodexx
- Roche Ltd
- Invitae Corporation
- Illumina
- Lilly Limited
- Mylan
- Natera
- PerkinElmer
- Quest Diagnostics
- Ravgen
- Sanofi Group
- Teva Pharmaceutical Ltd
The global alport syndrome treatment market size is expected to reach USD 19.00 million by 2032, according to a new study by Polaris Market Research. The report "Alport Syndrome Treatment Market Share, Size, Trends, Industry Analysis Report, By Product Type; By Disease Type; By Route Of Administration; By Distribution Channel (Online and Offline); By End User; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides an analysis of future market growth.
Market growth is primarily due to the increasing number of clinical studies for treating Alport syndromes. For instance, in February 2023, the first participants in the Phase 2 research of ELX-02 to treat Alport syndrome in patients with non-sense mutations have now been enrolled, as per the statement of Eloxx Pharmaceuticals. Around 8 Alport syndrome patients with non-sense mutations in the COL4 gene will be treated in this Phase 2 trial. Patients will receive two months of medication, followed by a three-month checkup.
Furthermore, the market is expanding due to rising technical developments in treating Alport syndrome. For instance, in July 2021, Bardoxolone methyl (RTA 402) was submitted as an NDA by Kyowa Kirin for the treatment of Alport Syndrome. The effectiveness and safety information from the CARDINAL Phase 3 clinical study, which Reata carried out for patients with Alport Syndrome, served as the foundation for this application. The firms that make up the Kyowa Kirin Group work to improve people's health and quality of life worldwide by generating new value by pursuing advancements in life sciences and technology. Therefore, the rising clinical trials for the treatment drive market growth over the forecast period.
Additionally, the market is anticipated to grow significantly due to significant investments made by major companies and government efforts for drug Research & Development (R&D) to treat Alport syndrome and associated symptoms. For instance, in August 2021, on the safety, effectiveness, and tolerability of spartan oral suspension and evaluating changes in proteinuria following once-daily dosage throughout a 108-week treatment period, Travere Therapeutics conducted a Phase II clinical research investigation. As a result, the market is anticipated to develop as diagnostic tests are adopted and made more widely available.
Alport Syndrome Treatment Market Report Highlights
The hospital pharmacy segment is anticipated to grow at a high CAGR over the forecast period hospitals are a crucial component of the healthcare business
Tablets in the Alport Syndrome Treatment Market are expected to witness significant growth due to convenience, technological advancements, and cost-effectiveness.
Asia Pacific holds a dominant market share. This results from the growing number of generic medicine producers and the frequency of renal failure and associated illnesses.
The global players include: AstraZeneca, Centogene, Eurofins, Roche Ltd., Quest Diagnostics, Ravgen, Sanofi Group, and Teva Pharmaceutical.
Polaris Market Research has segmented the alport syndrome treatment market report based on product type, disease type, route of administration, distribution channel, end-user, and region:
Alport Syndrome Treatment Market, Product Type Outlook (Revenue - USD Million, 2019 - 2032)
- Tablets
- Capsules
- Injectables
- Others
Alport Syndrome Treatment Market, Disease Type Outlook (Revenue - USD Million, 2019 - 2032)
- X-linked Alport Syndrome
- Autosomal Recessive Alport Syndrome
- Autosomal Dominant Alport Syndrome
Alport Syndrome Treatment Market, Route Of Administration Outlook (Revenue - USD Million, 2019 - 2032)
- Oral
- Parenteral
- Others
Alport Syndrome Treatment Market, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)
- Online
- Offline
Alport Syndrome Treatment Market, End User Outlook (Revenue - USD Million, 2019 - 2032)
- Hospital Pharmacy
- Retail Pharmacy
- Specialty Clinics
Alport Syndrome Treatment Market, Regional Outlook (Revenue - USD Million, 2019 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Latin America
- Argentina
- Brazil
- Mexico
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Alport Syndrome Treatment Market Insights
- 4.1. Alport Syndrome Treatment - Industry Snapshot
- 4.2. Alport Syndrome Treatment Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising prevalence of alport syndrome
- 4.2.1.2. Increase in the number of research and development activities
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Lack of skilled professionals
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTLE Analysis
- 4.5. Alport Syndrome Treatment Industry Trends
- 4.6. COVID-19 Impact Analysis
5. Global Alport Syndrome Treatment Market, by Product Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Alport Syndrome Treatment Market, by Product Type, 2019-2032 (USD Million)
- 5.3. Tablets
- 5.3.1. Global Alport Syndrome Treatment Market, by Tablets, by Region, 2019-2032 (USD Million)
- 5.4. Capsules
- 5.4.1. Global Alport Syndrome Treatment Market, by Capsules, by Region, 2019-2032 (USD Million)
- 5.5. Injectables
- 5.5.1. Global Alport Syndrome Treatment Market, by Injectables, by Region, 2019-2032 (USD Million)
- 5.6. Others
- 5.6.1. Global Alport Syndrome Treatment Market, by Others, by Region, 2019-2032 (USD Million)
6. Global Alport Syndrome Treatment Market, by Disease Type
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Alport Syndrome Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 6.3. X-linked Alport Syndrome
- 6.3.1. Global Alport Syndrome Treatment Market, by X-linked Alport Syndrome, by Region, 2019-2032 (USD Million)
- 6.4. Autosomal Recessive Alport Syndrome
- 6.4.1. Global Alport Syndrome Treatment Market, by Autosomal Recessive Alport Syndrome, by Region, 2019-2032 (USD Million)
- 6.5. Autosomal Dominant Alport Syndrome
- 6.5.1. Global Alport Syndrome Treatment Market, by Autosomal Dominant Alport Syndrome, by Region, 2019-2032 (USD Million)
7. Global Alport Syndrome Treatment Market, by Route Of Administration
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Alport Syndrome Treatment Market, by Route Of Administration, 2019-2032 (USD Million)
- 7.3. Oral
- 7.3.1. Global Alport Syndrome Treatment Market, by Oral, by Region, 2019-2032 (USD Million)
- 7.4. Parenteral
- 7.4.1. Global Alport Syndrome Treatment Market, by Parenteral, by Region, 2019-2032 (USD Million)
- 7.5. Others
- 7.5.1. Global Alport Syndrome Treatment Market, by Others, by Region, 2019-2032 (USD Million)
8. Global Alport Syndrome Treatment Market, by End User
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Global Alport Syndrome Treatment Market, by End User, 2019-2032 (USD Million)
- 8.3. Hospital Pharmacy
- 8.3.1. Global Alport Syndrome Treatment Market, by Hospital Pharmacy, by Region, 2019-2032 (USD Million)
- 8.4. Retail Pharmacy
- 8.4.1. Global Alport Syndrome Treatment Market, by Retail Pharmacy, by Region, 2019-2032 (USD Million)
- 8.5. Specialty Clinics
- 8.5.1. Global Alport Syndrome Treatment Market, by Specialty Clinics, by Region, 2019-2032 (USD Million)
9. Global Alport Syndrome Treatment Market, by Distribution Channel
- 9.1. Key Findings
- 9.2. Introduction
- 9.2.1. Global Alport Syndrome Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.3. Online
- 9.3.1. Global Alport Syndrome Treatment Market, by Online, by Region, 2019-2032 (USD Million)
- 9.4. Offline
- 9.4.1. Global Alport Syndrome Treatment Market, by Offline, by Region, 2019-2032 (USD Million)
10. Global Alport Syndrome Treatment Market, by Geography
- 10.1. Key findings
- 10.2. Introduction
- 10.2.1. Alport Syndrome Treatment Market Assessment, By Geography, 2019-2032 (USD Million)
- 10.3. Alport Syndrome Treatment Market - North America
- 10.3.1. North America: Alport Syndrome Treatment Market, by Product Type, 2019-2032 (USD Million)
- 10.3.2. North America: Alport Syndrome Treatment Market, by End User, 2019-2032 (USD Million)
- 10.3.3. North America: Alport Syndrome Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 10.3.4. North America: Alport Syndrome Treatment Market, by Route Of Administration, 2019-2032 (USD Million)
- 10.3.5. North America: Alport Syndrome Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 10.3.6. Alport Syndrome Treatment Market - U.S.
- 10.3.6.1. U.S.: Alport Syndrome Treatment Market, by Product Type, 2019-2032 (USD Million)
- 10.3.6.2. U.S.: Alport Syndrome Treatment Market, by End User, 2019-2032 (USD Million)
- 10.3.6.3. U.S.: Alport Syndrome Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 10.3.6.4. U.S.: Alport Syndrome Treatment Market, by Route Of Administration, 2019-2032 (USD Million)
- 10.3.6.5. U.S.: Alport Syndrome Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 10.3.7. Alport Syndrome Treatment Market - Canada
- 10.3.7.1. Canada: Alport Syndrome Treatment Market, by Product Type, 2019-2032 (USD Million)
- 10.3.7.2. Canada.: Alport Syndrome Treatment Market, by End User, 2019-2032 (USD Million)
- 10.3.7.3. Canada: Alport Syndrome Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 10.3.7.4. Canada: Alport Syndrome Treatment Market, by Route Of Administration, 2019-2032 (USD Million)
- 10.3.7.5. Canada: Alport Syndrome Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 10.4. Alport Syndrome Treatment Market - Europe
- 10.4.1. Europe: Alport Syndrome Treatment Market, by Product Type, 2019-2032 (USD Million)
- 10.4.2. Europe.: Alport Syndrome Treatment Market, by End User, 2019-2032 (USD Million)
- 10.4.3. Europe: Alport Syndrome Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 10.4.4. Europe: Alport Syndrome Treatment Market, by Route Of Administration, 2019-2032 (USD Million)
- 10.4.5. Europe: Alport Syndrome Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 10.4.6. Alport Syndrome Treatment Market - UK
- 10.4.6.1. UK: Alport Syndrome Treatment Market, by Product Type, 2019-2032 (USD Million)
- 10.4.6.2. UK.: Alport Syndrome Treatment Market, by End User, 2019-2032 (USD Million)
- 10.4.6.3. UK: Alport Syndrome Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 10.4.6.4. UK: Alport Syndrome Treatment Market, by Route Of Administration, 2019-2032 (USD Million)
- 10.4.6.5. UK: Alport Syndrome Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 10.4.7. Alport Syndrome Treatment Market - France
- 10.4.7.1. France: Alport Syndrome Treatment Market, by Product Type, 2019-2032 (USD Million)
- 10.4.7.2. France.: Alport Syndrome Treatment Market, by End User, 2019-2032 (USD Million)
- 10.4.7.3. France: Alport Syndrome Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 10.4.7.4. France: Alport Syndrome Treatment Market, by Route Of Administration, 2019-2032 (USD Million)
- 10.4.7.5. France: Alport Syndrome Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 10.4.8. Alport Syndrome Treatment Market - Germany
- 10.4.8.1. Germany: Alport Syndrome Treatment Market, by Product Type, 2019-2032 (USD Million)
- 10.4.8.2. Germany.: Alport Syndrome Treatment Market, by End User, 2019-2032 (USD Million)
- 10.4.8.3. Germany: Alport Syndrome Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 10.4.8.4. Germany: Alport Syndrome Treatment Market, by Route Of Administration, 2019-2032 (USD Million)
- 10.4.8.5. Germany: Alport Syndrome Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 10.4.9. Alport Syndrome Treatment Market - Italy
- 10.4.9.1. Italy: Alport Syndrome Treatment Market, by Product Type, 2019-2032 (USD Million)
- 10.4.9.2. Italy.: Alport Syndrome Treatment Market, by End User, 2019-2032 (USD Million)
- 10.4.9.3. Italy: Alport Syndrome Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 10.4.9.4. Italy: Alport Syndrome Treatment Market, by Route Of Administration, 2019-2032 (USD Million)
- 10.4.9.5. Italy: Alport Syndrome Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 10.4.10. Alport Syndrome Treatment Market - Spain
- 10.4.10.1. Spain: Alport Syndrome Treatment Market, by Product Type, 2019-2032 (USD Million)
- 10.4.10.2. Spain.: Alport Syndrome Treatment Market, by End User, 2019-2032 (USD Million)
- 10.4.10.3. Spain: Alport Syndrome Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 10.4.10.4. Spain: Alport Syndrome Treatment Market, by Route Of Administration, 2019-2032 (USD Million)
- 10.4.10.5. Spain: Alport Syndrome Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 10.4.11. Alport Syndrome Treatment Market - Netherlands
- 10.4.11.1. Netherlands: Alport Syndrome Treatment Market, by Product Type, 2019-2032 (USD Million)
- 10.4.11.2. Netherlands.: Alport Syndrome Treatment Market, by End User, 2019-2032 (USD Million)
- 10.4.11.3. Netherlands: Alport Syndrome Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 10.4.11.4. Netherlands: Alport Syndrome Treatment Market, by Route Of Administration, 2019-2032 (USD Million)
- 10.4.11.5. Netherlands: Alport Syndrome Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 10.4.12. Alport Syndrome Treatment Market - Russia
- 10.4.12.1. Russia: Alport Syndrome Treatment Market, by Product Type, 2019-2032 (USD Million)
- 10.4.12.2. Russia.: Alport Syndrome Treatment Market, by End User, 2019-2032 (USD Million)
- 10.4.12.3. Russia: Alport Syndrome Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 10.4.12.4. Russia: Alport Syndrome Treatment Market, by Route Of Administration, 2019-2032 (USD Million)
- 10.4.12.5. Russia: Alport Syndrome Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 10.5. Alport Syndrome Treatment Market - Asia Pacific
- 10.5.1. Asia Pacific: Alport Syndrome Treatment Market, by Product Type, 2019-2032 (USD Million)
- 10.5.2. Asia Pacific.: Alport Syndrome Treatment Market, by End User, 2019-2032 (USD Million)
- 10.5.3. Asia Pacific: Alport Syndrome Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 10.5.4. Asia Pacific: Alport Syndrome Treatment Market, by Route Of Administration, 2019-2032 (USD Million)
- 10.5.5. Asia Pacific: Alport Syndrome Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 10.5.6. Alport Syndrome Treatment Market - China
- 10.5.6.1. China: Alport Syndrome Treatment Market, by Product Type, 2019-2032 (USD Million)
- 10.5.6.2. China.: Alport Syndrome Treatment Market, by End User, 2019-2032 (USD Million)
- 10.5.6.3. China: Alport Syndrome Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 10.5.6.4. China: Alport Syndrome Treatment Market, by Route Of Administration, 2019-2032 (USD Million)
- 10.5.6.5. China: Alport Syndrome Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 10.5.7. Alport Syndrome Treatment Market - India
- 10.5.7.1. India: Alport Syndrome Treatment Market, by Product Type, 2019-2032 (USD Million)
- 10.5.7.2. India.: Alport Syndrome Treatment Market, by End User, 2019-2032 (USD Million)
- 10.5.7.3. India: Alport Syndrome Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 10.5.7.4. India: Alport Syndrome Treatment Market, by Route Of Administration, 2019-2032 (USD Million)
- 10.5.7.5. India: Alport Syndrome Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 10.5.8. Alport Syndrome Treatment Market - Japan
- 10.5.8.1. Japan: Alport Syndrome Treatment Market, by Product Type, 2019-2032 (USD Million)
- 10.5.8.2. Japan.: Alport Syndrome Treatment Market, by End User, 2019-2032 (USD Million)
- 10.5.8.3. Japan: Alport Syndrome Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 10.5.8.4. Japan: Alport Syndrome Treatment Market, by Route Of Administration, 2019-2032 (USD Million)
- 10.5.8.5. Japan: Alport Syndrome Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 10.5.9. Alport Syndrome Treatment Market - Malaysia
- 10.5.9.1. Malaysia: Alport Syndrome Treatment Market, by Product Type, 2019-2032 (USD Million)
- 10.5.9.2. Malaysia.: Alport Syndrome Treatment Market, by End User, 2019-2032 (USD Million)
- 10.5.9.3. Malaysia: Alport Syndrome Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 10.5.9.4. Malaysia: Alport Syndrome Treatment Market, by Route Of Administration, 2019-2032 (USD Million)
- 10.5.9.5. Malaysia: Alport Syndrome Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 10.5.10. Alport Syndrome Treatment Market - Indonesia
- 10.5.10.1. Indonesia: Alport Syndrome Treatment Market, by Product Type, 2019-2032 (USD Million)
- 10.5.10.2. Indonesia.: Alport Syndrome Treatment Market, by End User, 2019-2032 (USD Million)
- 10.5.10.3. Indonesia: Alport Syndrome Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 10.5.10.4. Indonesia: Alport Syndrome Treatment Market, by Route Of Administration, 2019-2032 (USD Million)
- 10.5.10.5. Indonesia: Alport Syndrome Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 10.5.11. Alport Syndrome Treatment Market - South Korea
- 10.5.11.1. South Korea: Alport Syndrome Treatment Market, by Product Type, 2019-2032 (USD Million)
- 10.5.11.2. South Korea.: Alport Syndrome Treatment Market, by End User, 2019-2032 (USD Million)
- 10.5.11.3. South Korea: Alport Syndrome Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 10.5.11.4. South Korea: Alport Syndrome Treatment Market, by Route Of Administration, 2019-2032 (USD Million)
- 10.5.11.5. South Korea: Alport Syndrome Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 10.6. Alport Syndrome Treatment Market - Middle East & Africa
- 10.6.1. Middle East & Africa: Alport Syndrome Treatment Market, by Product Type, 2019-2032 (USD Million)
- 10.6.2. Middle East & Africa: Alport Syndrome Treatment Market, by End User, 2019-2032 (USD Million)
- 10.6.3. Middle East & Africa: Alport Syndrome Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 10.6.4. Middle East & Africa: Alport Syndrome Treatment Market, by Route Of Administration, 2019-2032 (USD Million)
- 10.6.5. Middle East & Africa: Alport Syndrome Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 10.6.6. Alport Syndrome Treatment Market - Saudi Arabia
- 10.6.6.1. Saudi Arabia: Alport Syndrome Treatment Market, by Product Type, 2019-2032 (USD Million)
- 10.6.6.2. Saudi Arabia.: Alport Syndrome Treatment Market, by End User, 2019-2032 (USD Million)
- 10.6.6.3. Saudi Arabia: Alport Syndrome Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 10.6.6.4. Saudi Arabia: Alport Syndrome Treatment Market, by Route Of Administration, 2019-2032 (USD Million)
- 10.6.6.5. Saudi Arabia: Alport Syndrome Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 10.6.7. Alport Syndrome Treatment Market - UAE
- 10.6.7.1. UAE: Alport Syndrome Treatment Market, by Product Type, 2019-2032 (USD Million)
- 10.6.7.2. UAE.: Alport Syndrome Treatment Market, by End User, 2019-2032 (USD Million)
- 10.6.7.3. UAE: Alport Syndrome Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 10.6.7.4. UAE: Alport Syndrome Treatment Market, by Route Of Administration, 2019-2032 (USD Million)
- 10.6.7.5. UAE: Alport Syndrome Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 10.6.8. Alport Syndrome Treatment Market - Israel
- 10.6.8.1. Israel: Alport Syndrome Treatment Market, by Product Type, 2019-2032 (USD Million)
- 10.6.8.2. Israel.: Alport Syndrome Treatment Market, by End User, 2019-2032 (USD Million)
- 10.6.8.3. Israel: Alport Syndrome Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 10.6.8.4. Israel: Alport Syndrome Treatment Market, by Route Of Administration, 2019-2032 (USD Million)
- 10.6.8.5. Israel: Alport Syndrome Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 10.6.9. Alport Syndrome Treatment Market - South Africa
- 10.6.9.1. South Africa: Alport Syndrome Treatment Market, by Product Type, 2019-2032 (USD Million)
- 10.6.9.2. South Africa.: Alport Syndrome Treatment Market, by End User, 2019-2032 (USD Million)
- 10.6.9.3. South Africa: Alport Syndrome Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 10.6.9.4. South Africa: Alport Syndrome Treatment Market, by Route Of Administration, 2019-2032 (USD Million)
- 10.6.9.5. South Africa: Alport Syndrome Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 10.7. Alport Syndrome Treatment Market - Latin America
- 10.7.1. Latin America: Alport Syndrome Treatment Market, by Product Type, 2019-2032 (USD Million)
- 10.7.2. Latin America.: Alport Syndrome Treatment Market, by End User, 2019-2032 (USD Million)
- 10.7.3. Latin America: Alport Syndrome Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 10.7.4. Latin America: Alport Syndrome Treatment Market, by Route Of Administration, 2019-2032 (USD Million)
- 10.7.5. Latin America: Alport Syndrome Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 10.7.6. Alport Syndrome Treatment Market - Mexico
- 10.7.6.1. Mexico: Alport Syndrome Treatment Market, by Product Type, 2019-2032 (USD Million)
- 10.7.6.2. Mexico.: Alport Syndrome Treatment Market, by End User, 2019-2032 (USD Million)
- 10.7.6.3. Mexico: Alport Syndrome Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 10.7.6.4. Mexico: Alport Syndrome Treatment Market, by Route Of Administration, 2019-2032 (USD Million)
- 10.7.6.5. Mexico: Alport Syndrome Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 10.7.7. Alport Syndrome Treatment Market - Brazil
- 10.7.7.1. Brazil: Alport Syndrome Treatment Market, by Product Type, 2019-2032 (USD Million)
- 10.7.7.2. Brazil.: Alport Syndrome Treatment Market, by End User, 2019-2032 (USD Million)
- 10.7.7.3. Brazil: Alport Syndrome Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 10.7.7.4. Brazil: Alport Syndrome Treatment Market, by Route Of Administration, 2019-2032 (USD Million)
- 10.7.7.5. Brazil: Alport Syndrome Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 10.7.8. Alport Syndrome Treatment Market - Argentina
- 10.7.8.1. Argentina: Alport Syndrome Treatment Market, by Product Type, 2019-2032 (USD Million)
- 10.7.8.2. Argentina.: Alport Syndrome Treatment Market, by End User, 2019-2032 (USD Million)
- 10.7.8.3. Argentina: Alport Syndrome Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 10.7.8.4. Argentina: Alport Syndrome Treatment Market, by Route Of Administration, 2019-2032 (USD Million)
- 10.7.8.5. Argentina: Alport Syndrome Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
11. Competitive Landscape
- 11.1. Expansion and Acquisition Analysis
- 11.1.1. Expansion
- 11.1.2. Acquisitions
- 11.2. Partnerships/Collaborations/Agreements/Exhibitions
12. Company Profiles
- 12.1. AstraZeneca
- 12.1.1. Company Overview
- 12.1.2. Financial Performance
- 12.1.3. Product Benchmarking
- 12.1.4. Recent Development
- 12.2. Centogene
- 12.2.1. Company Overview
- 12.2.2. Financial Performance
- 12.2.3. Product Benchmarking
- 12.2.4. Recent Development
- 12.3. Eurofins Discovery
- 12.3.1. Company Overview
- 12.3.2. Financial Performance
- 12.3.3. Product Benchmarking
- 12.3.4. Recent Development
- 12.4. Eurofins LifeCodexx
- 12.4.1. Company Overview
- 12.4.2. Financial Performance
- 12.4.3. Product Benchmarking
- 12.4.4. Recent Development
- 12.5. Roche Ltd
- 12.5.1. Company Overview
- 12.5.2. Financial Performance
- 12.5.3. Product Benchmarking
- 12.5.4. Recent Development
- 12.6. Invitae Corporation
- 12.6.1. Company Overview
- 12.6.2. Financial Performance
- 12.6.3. Product Benchmarking
- 12.6.4. Recent Development
- 12.7. Illumina
- 12.7.1. Company Overview
- 12.7.2. Financial Performance
- 12.7.3. Product Benchmarking
- 12.7.4. Recent Development
- 12.8. Lilly Limited
- 12.8.1. Company Overview
- 12.8.2. Financial Performance
- 12.8.3. Product Benchmarking
- 12.8.4. Recent Development
- 12.9. Mylan
- 12.9.1. Company Overview
- 12.9.2. Financial Performance
- 12.9.3. Product Benchmarking
- 12.9.4. Recent Development
- 12.10. Natera
- 12.10.1. Company Overview
- 12.10.2. Financial Performance
- 12.10.3. Product Benchmarking
- 12.10.4. Recent Development
- 12.11. PerkinElmer
- 12.11.1. Company Overview
- 12.11.2. Financial Performance
- 12.11.3. Product Benchmarking
- 12.11.4. Recent Development
- 12.12. Quest Diagnostics
- 12.12.1. Company Overview
- 12.12.2. Financial Performance
- 12.12.3. Product Benchmarking
- 12.12.4. Recent Development
- 12.13. Ravgen
- 12.13.1. Company Overview
- 12.13.2. Financial Performance
- 12.13.3. Product Benchmarking
- 12.13.4. Recent Development
- 12.14. Sanofi Group
- 12.14.1. Company Overview
- 12.14.2. Financial Performance
- 12.14.3. Product Benchmarking
- 12.14.4. Recent Development
- 12.15. Teva Pharmaceutical Ltd
- 12.15.1. Company Overview
- 12.15.2. Financial Performance
- 12.15.3. Product Benchmarking
- 12.15.4. Recent Development
비교리스트